By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Neuraltus Pharmaceuticals, Inc. 

2483 E. Bayshore Road
Suite 212
Palo Alto  California  94303   U.S.A.
Phone: 650-424-1600 Fax: 650-320-8504



Company News
Neuraltus Pharmaceuticals, Inc. Announces Plans For Second Phase 2 Study Of NP001 In ALS Using Biomarker For Enriched Patient Selection 4/4/2016 6:55:00 AM
Biomarker Analyses Of Neuraltus Pharmaceuticals, Inc.' NP001 Phase 2 Data Demonstrate Potential For Treating ALS Patients With Systemic Inflammation 4/4/2016 6:51:38 AM
Investigator To Receive $1.5 Million Grant From The ALS Association To Help Fund Confirmatory Phase 2 Study Of Neuraltus Pharmaceuticals, Inc.' NP001 7/1/2015 6:46:07 AM
Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals, Inc.'s NP001 Potential Efficacy And Safety In ALS 4/20/2015 7:12:39 AM
Neuraltus Pharmaceuticals, Inc.' ALS Treatment Candidate, NP001, Highlighted At ALS Research Group Summit 9/17/2014 8:41:55 AM
Neuraltus Pharmaceuticals, Inc.' NP001 Phase 2 Results Highlighted At The 24th International Symposium On ALS/MND 12/9/2013 7:48:47 AM
Neuraltus Pharmaceuticals, Inc. Seeks $30 Million for New Lou Gehrig's Disease Drug Trial 10/10/2013 7:36:59 AM
Neuraltus Pharmaceuticals, Inc. Names Richard L. Casey as President and Chief Executive Officer 10/8/2013 6:22:20 AM
Cannabis Science Inc. Appoints Michael McGrath, MD, PhD, Professor, Departments of Laboratory Medicine, Pathology, and Medicine, University of California, San Francisco (UCSF), and Co-Founder of Biotechs Pathologica LLC and Neuraltus Pharmaceuticals, Inc., to the Company's Scientific Advisory Board 3/28/2013 6:36:33 AM
Neuraltus Pharmaceuticals, Inc. Announces Phase 2 Clinical Results for NP001 in Patients With Amyotrophic Lateral Sclerosis (ALS) 10/30/2012 9:42:34 AM